PLATO was designed to test the hypothesis that ticagrelor, a novel P2Y12 platelet inhibitor would result in a lower risk for recurrent thrombotic events as compared with clopidogrel in a broad population of patients presenting with acute coronary syndromes. Join Drs. Bhatt, Harrington, Nicolau, and Mehran as they discuss this important trial.

Thrombosis-associated major adverse cardiac events (MACE) occur in acute coronary syndromes (ACS) despite treatment with existing antiplatelet regimens. This review will examine the literature to define the extent and potential reasons for excess thrombotic events in both invasively and medically managed populations. Including video interviews with Drs. Becker, Cannon, and Wallentin.